Market Overview

UPDATE: Goldman Sachs Upgrades Thoratec Corporation to CL-Buy, Raises PT


In a report published Monday, Goldman Sachs Group upgraded its rating on Thoratec Corporation (NASDAQ: THOR) to CL-Buy, and raised its price target from $46.00 to $48.00.

Goldman Sachs noted, “We add shares of Thoratec (THOR) to the Americas Conviction Buy List with a $48 12-month price target, implying 29.0% upside from current levels. Our investment thesis is based on our view that: (1) Thoratec should maintain its leadership position in the growing LVAD, representing a source of significant upside to consensus numbers; (2) the company's competitive position looks to be strengthening with the expansion to new market segments; (3) a solid pipeline should support multi-year growth; and (4) Thoratec has ample financial flexibility to reinvest in the business with attractive returns. We see these dynamics making THOR a compelling fundamental and strategic asset, particularly in the context of limited long-duration product cycles in healthcare with outsized profitability.”

Thoratec Corporation closed on Friday at $37.20.

Latest Ratings for THOR

Sep 2015UpgradesMarket PerformOutperform
Aug 2015DowngradesOutperformMarket Perform
Aug 2015DowngradesOutperformMarket Perform

View More Analyst Ratings for THOR
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Upgrades Analyst Ratings


Related Articles (THOR)

View Comments and Join the Discussion!

Latest Ratings

HUBBInitiates Coverage On160.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT on HeartWare International

Ford Plans Bold Rebrand for Lincoln